VBL Therapeutics In-Person KOL Event on Ovarian Cancer
About The Event
The luncheon will feature presentations and a panel discussion with Key Opinion Leaders (KOL’s) Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine; Creighton University School of Medicine), Richard Penson, MBBS (Massachusetts General Hospital) and Kathleen Moore, MD (OU College of Medicine), who will discuss the current treatment landscape and unmet medical need in treating patients with ovarian cancer. The live event will be hosted by Dror Harats, MD (CEO of VBL Therapeutics).
VBL Therapeutics’ lead product candidate ofra-vec (ofranergene obadenovec; VB-111) will be discussed as a potential treatment solution for platinum resistant ovarian cancer. Ofra-vec utilizes the VTS™ platform and is being evaluated in VBL’s registration enabling OVAL Phase 3 study. Ofra-vec’s mechanism of action is designed to combine the blockade of tumor microvasculature (the blood vessels required for tumor growth) with an anti-tumor immune response. OVAL is now fully enrolled with 409 patients and topline data are expected in 2H 2022.
A live question and answer session will follow.